GRI BIO, INC.

GRI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020 Jun 2020
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $1.3M $2.0M $215.0K $1.2M $1.8M $1.3M $733.0K $808.0K
SG&A Expense $1.4M $1.1M $1.0M $1.1M $830.0K $179.0K $300.0K $327.0K
Operating Income $-2.6M $-3.1M $-1.3M $-2.3M $-2.6M $-1.5M $-1.0M $-1.1M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense $0
Net Income $-302.0K $-3.1M $-1.3M $-2.3M $-2.6M $-1.5M $-1.0M $-1.1M
Net Margin
EPS (Basic) $-0.19 $-0.01 $0.00 $-0.01 $-0.01 $-0.01 $0.00 $0.00
EPS (Diluted) $-0.19 $-0.01 $0.00 $-0.01 $-0.01 $-0.01 $0.00 $0.00
Shares Outstanding (Basic) 13.6M 392.5M 408.8M 408.8M 342.6M 270.4M 270.4M 270.4M
Shares Outstanding (Diluted) 13.6M 392.5M 408.8M 408.8M 342.6M 270.4M 270.4M 270.4M
Dividends Per Share
← Newer Page 1 of 2 Older →